References
- Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H, et al. 2015. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 5(2):020415–020415. https://doi.org/https://doi.org/10.7189/jogh.05-020415.
- Allen NM, Hacohen Y, Palace J, Beeson D, Vincent A, Jungbluth H. 2016. Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome. Neurology. 86(7):692–694. https://doi.org/https://doi.org/10.1212/WNL.0000000000002382.
- Alvarado-Gonzalez A, Arce I. 2015. Tiotropium bromide in chronic obstructive pulmonary disease and bronchial asthma. J Clin Med Res. 7(11):831–839. https://doi.org/https://doi.org/10.14740/jocmr2305w.
- Bourbeau J, Sedeno MF, Metz K, Li PZ, Pinto L. 2016. Early COPD exacerbation treatment with combination of ICS and LABA for patients presenting with mild-to-moderate worsening of dyspnea. COPD. 13(4):439–447. https://doi.org/https://doi.org/10.3109/15412555.2015.1101435.
- Cazzola M, Rogliani P, Ora J, Matera MG. 2015. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 8(5):529–539. https://doi.org/https://doi.org/10.1586/17512433.2015.1075389.
- Hartman S, Merkus P, Maseland M, Roovers L, van Setten P. 2015. Hypokalaemia in children with asthma treated with nebulised salbutamol. Arch Dis Child. 100(10):970–972. https://doi.org/https://doi.org/10.1136/archdischild-2015-308427.
- Heys D, Swain A, Knowles S, Waugh A, Bailey M. 2018. An audit of change in clinical practice: from oxygen-driven to air-driven nebulisers for prehospital patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Intern Med J. 48(6):668–673. https://doi.org/https://doi.org/10.1111/imj.13684.
- Jacobson GA, Raidal S, Robson K, Narkowicz CK, Nichols DS, Haydn Walters E. 2017. Bronchopulmonary pharmacokinetics of (R)-salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses. Br J Clin Pharmacol. 83(7):1436–1445. https://doi.org/https://doi.org/10.1111/bcp.13228.
- Jing Z, Chun C, Ning S, Hong Z, Bei H, Wan-Zhen Y. 2016. Systemic inflammatory marker CRP Was better predictor of readmission for AECOPD than sputum inflammatory markers. Arch Bronconeumol. 52(3):138–144. https://doi.org/https://doi.org/10.1016/j.arbres.2015.01.011.
- Kaufman JS. 2017. Acute exacerbation of COPD: diagnosis and management. Nurse Pract. 42(6):1–7. https://doi.org/https://doi.org/10.1097/01.NPR.0000515997.35046.b8.
- Kiser TH, Vandivier RW. 2015. Severe acute exacerbations of chronic obstructive pulmonary disease: does the dosage of corticosteroids and type of antibiotic matter? Curr Opin Pulm Med. 21(2):142–148. https://doi.org/https://doi.org/10.1097/MCP.0000000000000142.
- Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, et al. 2018. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 378(18):1671–1680. https://doi.org/https://doi.org/10.1056/NEJMoa1713901.
- Liu S, Chen J, He Y, Wu L, Lai J, Zuo J, Yang L, Guo X. 2017. Comparative effectiveness of six Chinese herb formulas for acute exacerbation of chronic obstructive pulmonary disease: protocol for systematic review and network meta-analysis. BMJ Open. 7(8):e017099–e017099. https://doi.org/https://doi.org/10.1136/bmjopen-2017-017099.
- Lötvall J, Lunde H, Svedmyr N. 1998. Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients. Can Respir J. 5(3):191–194. https://doi.org/https://doi.org/10.1155/1998/364639.
- Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson S, Östlund O, Anzueto A. 2015. A score to predict short-term risk of COPD exacerbations (SCOPEX). Int J Chron Obstruct Pulmon Dis. 10:201–209. https://doi.org/https://doi.org/10.2147/COPD.S69589.
- Morantes-Caballero JA, Fajardo Rodriguez HA. 2019. Effects of air pollution on acute exacerbation of chronic obstructive pulmonary disease: a descriptive retrospective study (pol-AECOPD). Int J Chron Obstruct Pulmon Dis. 14:1549–1557. https://doi.org/https://doi.org/10.2147/COPD.S192047.
- Ohbayashi H. 2017. Comparison of the rapid effects of single inhalations of formoterol and tiotropium bromide on respiratory function and COPD symptoms in a randomized crossover study. Respir Investig. 55(6):348–356. https://doi.org/https://doi.org/10.1016/j.resinv.2017.07.004.
- Panahi Y, Ghanei M, Behzadi M, Salehi M, Soflaei SS, Sahebkar A. 2016. Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease: A randomized comparative trial. Saudi Pharm J. 24(2):147–152. https://doi.org/https://doi.org/10.1016/j.jsps.2015.01.005.
- Rabe KF. 2007. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med. 176:532–555.
- Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myllärniemi M, Saarto T. 2017. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 3(4):00084–2017. https://doi.org/https://doi.org/10.1183/23120541.00084-2017.
- Santus P, Buccellati C, Centanni S, Fumagalli F, Busatto P, Blasi F, Sala A. 2012. Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacol Res. 66(4):343–348. https://doi.org/https://doi.org/10.1016/j.phrs.2012.05.007.
- Tan DBA, Armitage J, Teo T-H, Ong NE, Shin H, Moodley YP. 2017. Elevated levels of circulating exosome in COPD patients are associated with systemic inflammation. Respir Med. 132:261–264. https://doi.org/https://doi.org/10.1016/j.rmed.2017.04.014.
- Tee AK. 2017. Chronic obstructive pulmonary disease (COPD): “not a cigarette only pulmonary disease”. Ann Acad Med Singapore. 46(11):415–416.
- Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA. 2015. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Int J Chron Obstruct Pulmon Dis. 10:2055–2066. https://doi.org/https://doi.org/10.2147/COPD.S90658.
- Vogelmeier CF, Bateman ED, Pallante J, Alagappan VKT, D'Andrea P, Chen H, Banerji D. 2013. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 1(1):51–60. https://doi.org/https://doi.org/10.1016/S2213-2600(12)70052-8.
- Wei X, Yu N, Ding Q, Ren J, Mi J, Bai L, Li J, Qi M, Guo Y. 2018. The features of AECOPD with carbon dioxide retention. BMC Pulm Med. 18(1):124–124. https://doi.org/https://doi.org/10.1186/s12890-018-0691-8.
- Wolfe GI, Silvestri NJ. 2016. Comment: Salbutamol—a means to an endplate. Neurology. 86(7):693–693. https://doi.org/https://doi.org/10.1212/WNL.0000000000002385.
- Xiong G, Xu L, Wei L, Li X. 2008. Atomization inhalation of terbutaline and budesonide efficiently improved immunity and lung function of AECOPD patients. Cell Mol Immunol. 5(4):287–291. https://doi.org/https://doi.org/10.1038/cmi.2008.35.
- Yao C, Liu X, Tang Z. 2017. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis. 12:2285–2290. https://doi.org/https://doi.org/10.2147/COPD.S141760.
- Yohannes AM, Mülerová H, Lavoie K, Vestbo J, Rennard SI, Wouters E, Hanania NA. 2017. The association of depressive symptoms with rates of acute exacerbations in patients with COPD: results from a 3-year longitudinal follow-up of the ECLIPSE cohort. J Am Med Dir Assoc. 18(11):955–959.e6. https://doi.org/https://doi.org/10.1016/j.jamda.2017.05.024.